ClinicalTrials.gg
RecruitingNCT06663306Updated Mar 2, 2026

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

A Phase 1 interventional study of Pemetrexed and Bevacizumab in Lung Cancer (NSCLC) and Leptomeningeal Metastasis, sponsored by Shanghai Chest Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Shanghai Chest Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 71 studies testing pemetrexed in Lung Neoplasms — 6 open to participants now, 10 under way, 4 of them phase 3. Pemetrexed · Lung Neoplasms.

Planned enrollment
55th of 69
19 · median 48
Started
2024
with 2 others
Phase 1
6 of 71
1 open now
Registered
71st of 71
by date

Among the 71 studies testing pemetrexed in Lung Neoplasms, this one is the 55th largest by planned enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 71st registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 71 studies testing pemetrexed in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing pemetrexed in Lung Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.

03

Conditions studied

  • Lung Cancer (NSCLC)
  • Leptomeningeal Metastasis

Keywords

  • Leptomeningeal Metastases
  • NSCLC
  • Intrathecal Injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • PS score 0-3. ECOG PS score 2 or 3 should be due to .
  • Patients with diagnosed non-small cell lung cancer with cerebrospinal fluid and/or MRI diagnosis of leptomeningeal metastasis(LM);
  • Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard systemic anti-tumor treatment;
  • Expected survival time ≥ 1 month;
  • The laboratory test results meet the following criteria: ≥ 90 g/L, ≥ 1.5 × 10\^9/L, count ≥ 100 × 10\^9/L; Total ≤ 1.5 times the (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN ; Creatinine≤ 2.0 × ULN,or rate (CrCl) ≥ 50 mL/min;
  • Females of agree to use during the study period and for 6 months after the completion of the study; patients who have had a negative serum or urine pregnancy test within seven days prior to enrollment in the study and who are not breastfeeding; and males agreeing to use contraception during the study period and for 6 months after the completion of the study;
  • Understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Positive for (HIV) ;
  • History of allergy to pemetrexed or bevacizumab;
  • History of pemetrexed and/or bevacizumab intrathecal Injection;
  • Presence of of bevacizumab:

    1. Uncontrolled hypertension(systolic pressure≥150mmHg,or diastolic pressure≥100mmHg;History of hypertensive crisis or hypertensive encephalopathy;
    2. Urine protein≥2+,or 24-hour urine protein≥2g;
    3. Unstable angina pectoris, symptomatic congestive heart failure,myocardial infarction within 6 months before enrollment, severe vascular disease, severe uncontrolled arrhythmia;
    4. Major hemoptysis within the past 1 month; History of coagulation disorders;
    5. Presence of serious non-healing wounds, ulcers, or bone fractures
    6. Presence of abdominal fistula, gastrointestinal perforation, or gastrointestinal tract obstruction;
    7. Presence of macrovascular invasion;
    8. Some neurological disorders unrelated to tumors,such as intracranial infection,cerebral hemorrhage,cerebral infarction,encephalitis;
  • Brain/spinal cord radiation therapy within 1 week before enrollment;
  • Pregnant and lactating female;
  • Refuse to use during the study period;
  • Individuals considered by the investigator to be unsuitable for enrollment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    Arm A

    Enrolled patients were treated with pemetrexed intrathecal injection

    Drug: Pemetrexed

  • Experimental
    Arm B

    Enrolled patients were treated with pemetrexed combined with bevacizumab intrathecal injection

    Drug: Pemetrexed · Drug: Bevacizumab

Interventions

  • Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks

  • Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (Safety and Tolerability)

    Number of participants with adverse events, treatment emergent adverse events,and serious adverse events assessed by CTCAE v5.0 as a measure of safety and tolerability.

    Time frame: From the beginning of the treatment until two months after the treatment.

Secondary outcomes

  1. Overall Survival (OS)

    Kaplan-Meier method used to estimate the distribution of OS from the start of study treatment.

    Time frame: Up to 2 years

Other outcomes

  1. Clinical response rate

    The evaluation of clinical response rate was assessed by the investigators, which based on improvement of neurologic symptoms/signs and changes in the Karnofsky performance status score . This evaluation consists of five layers, including complete response (CR), obvious response (OR), partial response (PR), stable disease (SD) and progressive disease (PD).Clinical response was defined as the continuous presence of CR, OR or PR within an interval of at least 1 week. SD and PD were defined as ineffective.

    Time frame: Up to 2 years

  2. CSF cytology

    Cerebrospinal fluid (CSF) was collected before each cycle of intrathecal treatment, and assessed by the investigators the presence of tumor cells (Positive or Nagetive).

    Time frame: From the beginning of the intrathecal treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

  3. Radiographic assessment

    Radiographic assessment with complete contrast-enhanced neuro-axis MRI or CT, Leptomeningeal metastases response was evaluated using the Response Assessment in Neuro-Oncology (RANO) criteria.

    Time frame: From the beginning of the treatment until two months after the treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kuang Y, Teng J, Wang W, Zhang B, Cheng L, Zhang Y, Liu W, Gao Z, Nie W, Xiong L, Shi C, Zhang W, Lou Y, Han B, Zhong H. Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial. BMJ Open. 2026 Mar 23;16(3):e116187. doi: 10.1136/bmjopen-2026-116187. PubMed 41877338 ↗

Individual participant data

Plan to share: Yes — Deidentified individual participant data that underlie the results reported in this study will be made available upon reasonable request from the corresponding author, subject to institutional review and applicable regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 164 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 36 months is below that.

Counting every sponsor, half of 294 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Oct 29, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06663306
Responsible party
Hua Zhong (Chief of Respiratory Department, Shanghai Chest Hospital) — Principal investigator
First posted
Oct 29, 2024
Start date
Dec 9, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Hua Zhong, MD
Contact
eddiedong8@hotmail.com
+86 021-22200000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion